UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

                               SEPTEMBER 25, 2006
                Date of Report (Date of earliest event reported)

                               EPICEPT CORPORATION
--------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

          DELAWARE                    000-51290                  52-1841431
--------------------------------------------------------------------------------
(State or other jurisdiction        (Commission               (IRS Employer
         of incorporation)          File Number)             Identification No.)

            270 SYLVAN AVENUE
      ENGLEWOOD CLIFFS, NEW JERSEY                                  07632
--------------------------------------------------------------------------------
(Address of principal executive offices)                         (Zip Code)

                                 (201) 894-8980
              (Registrant's telephone number, including area code)


     Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[_]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[_]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[_]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[_]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))






ITEM 8.01         OTHER EVENTS.

                  On September 25, 2006, EpiCept Corporation, a Delaware
         corporation (the "Registrant"), issued a press release announcing that
         Myriad Genetics, Inc. (Nasdaq: MYGN) has reported positive clinical
         results for Azixa(TM), a compound discovered by the Registrant and
         licensed to Myriad as part of an exclusive, worldwide development and
         commercialization agreement. Based on these results, Myriad intends to
         initiate Phase II clinical trials for the drug this fall, triggering a
         milestone payment to the Registrant.

                  Myriad Genetics has reported that in a Phase I study of Azixa
         in cancer that has metastasized to the brain, the drug achieved its
         maximum tolerated dose in patients. Myriad also noted a measured
         reduction in tumor size in certain patients, suggesting evidence of
         activity. Myriad has stated that it is finalizing the therapeutic dose
         and regimen to bring Azixa forward to Phase II trials shortly.

                  On September 27, 2006 the Registrant also announced several
         important findings revealed from an ongoing analysis of its previously
         reported Phase III clinical trial results for LidoPAIN SP, the
         Company's sterile prescription analgesic patch designed to provide
         sustained topical delivery of licocaine to a post-surgical or
         post-traumatic sutured wound. The Company is studying the impact of
         these findings in conjunction with other data generated from the trial
         in order to determine what changes in trial design could be made to
         improve the likelihood of a positive result in a subsequent trial.


ITEM 9.01         FINANCIAL STATEMENTS AND EXHIBITS
                  (c) Exhibits

                  99.1     Press release of EpiCept Corporation, dated September
                           25, 2006.

                  99.2     Press release of EpiCept Corporation, dated September
                           27, 2006.






                                       2







                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                            EPICEPT CORPORATION


                                              /s/ Robert W. Cook
                                            ------------------------------
                                            Name:  Robert W. Cook
                                            Title: Chief Financial Officer

Date:  September 29, 2006












                                       3







                                  EXHIBIT INDEX

EXHIBIT                                           DESCRIPTION
-------                                           -----------

  99.1        Press release of EpiCept Corporation, dated September 25, 2006.
  99.2        Press release of EpiCept Corporation, dated September 27 2006.



























                                       4